Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) EBITDA: 2021-2024

Historic EBITDA for Immunocore Holdings (IMCR) over the last 4 years, with Dec 2024 value amounting to -$48.6 million.

  • Immunocore Holdings' EBITDA fell 129.78% to -$3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.1 million, marking a year-over-year decrease of 23.06%. This contributed to the annual value of -$48.6 million for FY2024, which is 31.77% down from last year.
  • Latest data reveals that Immunocore Holdings reported EBITDA of -$48.6 million as of FY2024, which was down 31.77% from -$36.9 million recorded in FY2023.
  • Over the past 5 years, Immunocore Holdings' EBITDA peaked at -$36.9 million during FY2023, and registered a low of -$180.3 million during FY2021.
  • Over the past 3 years, Immunocore Holdings' median EBITDA value was -$48.6 million (recorded in 2024), while the average stood at -$54.1 million.
  • Per our database at Business Quant, Immunocore Holdings' EBITDA spiked by 57.34% in 2022 and then plummeted by 31.77% in 2024.
  • Over the past 4 years, Immunocore Holdings' EBITDA (Yearly) stood at -$180.3 million in 2021, then surged by 57.34% to -$76.9 million in 2022, then surged by 52.05% to -$36.9 million in 2023, then plummeted by 31.77% to -$48.6 million in 2024.